Scientific supervisor : Prof Dr. B.I.Polyakov Dr . A.F. Marebuch Presented by Dr. Khant Zaw Aung Gemcitabine/Cisplatin And Paclitexal/Carboplatin Combinations In Treatment Of Non-small Cell Lung Cancer Stage IIIB And IV As First Line Of Treatment (ECOG PS <2) M.V. Lomonosov Moscow State University Faculty of Basic Medicine
There are many risk factors of NSCLC but the primary risk factor for lung cancer is smoking , which account for >85% of lung cancer related death.
The treatment of NSCLC is based upon the stage of the disease. In early stage, surgery followed by chemotherapy ,biotherapy and radiotherapy is main stay but in the late stage the prognosis is poor. So chemotherapy is the main stay in late stage.
To study the efficacy and toxicities of treatment of gemcitabine/cisplatin combination and paclitexal /carboplatin combination in NSCLC stage IIIB and IV patients of ECOG PS<2 as first line chemotherapy.
53 Patients Gemcitabine 1,000-1,2500 mg/m2 IV over 30 minutes on day 1 and 8 + Cisplatin 50-80 mg/m2 IV over 1 hr on day 1 Paclitexal 175-200mg/m2 IV over 3 hrs on day 1 + Carboplatin (AUC 5 or 6) IV over 30 minutes on day 1 29 patients 24 patients Proper premdications, antiemetic therapy and prehydration therapy before treatment. Proper premdications and standard antiemetic therapy before treatment Cycles are repeated at 3 weeks interval.
After completing the primary therapy, patients were followed up annually. Follow-up included physical examination, blood chemistry and evaluation of tumour markers , chest X-ray, upper abdominal ultrasonography.
Computerized tomography and magnetic resonance imaging (MRI) were done if required.
According to the patient’s status, response to treatment and progression, further therapy are given.
Early stage of non-small cell lung cancer can be cured by surgery followed by chemotherapy, radiotherapy and biotherapy but we will know that it can be recurrent. So follow up after the treatment is also important .
Smoking is the major risk factor for non-small cell lung cancer.So that we must educate the people not to smoke and we must do the health education programme for prevention of the disease.
Because of the poor prognosis of the late stage of non-small cell lung cancer, the aim of this stage is to support the quality of life ,to relieve the symptoms and to longer the duration of life.